Journal
AIDS
Volume 23, Issue 15, Pages 1971-1975Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e32832c96e9
Keywords
antiretroviral; kidney; nephrotoxicity; nucleoside analog reverse transcriptase inhibitor; protease inhibitor; renal; tenofovir
Categories
Funding
- National Institutes of Health [R01 DA11602, K24 DA00432]
- Gilead Sciences
- Gilead
- Merck
- Pfizer
- Roche
- Tibotec
Ask authors/readers for more resources
Objectives: To determine whether tenofovir disoproxil fumarate (TDF) is associated with renal dysfunction when used as part of an initial antiretroviral regimen and to assess the effect of ritonavir-boosted protease inhibitor (PI/r) coadministration on renal function in TDF-treated patients. Design: Analysis from a prospective observational cohort. Methods: We compared all anti retroviral-naive patients with an estimated glomerular filtration rate (eGFR) of more than 50 ml/min per 1.73 m(2) (modification of diet in renal disease equation) who initiated either TDF (n = 201) or any alternative nucleoside reverse transcriptase inhibitor (NRTI) (n = 231) after 1 January 2002. Results: Patients taking both TDF and NRTIs experienced an initial decline in eGFR during the first 180 days of therapy, but eGFR stabilized between 180 and 720 days. There was no difference between TDF and NRTI use in 25 or 50% decline in eGFR at 1 or 2 years or in change in eGFR at 6, 12, or 24 months. Those taking TDF and a PI/r had a greater median decline in eGFR than those taking TDF and a non-NRTI at 6 months (P = 0.01), with trends at 12 (P = 0.08) and 24 months (P = 0.08). There was no difference in median GFR decline between those on an NRTI and PI/r vs: an NRTI and non-NRTI. Conclusion: Our data are consistent with results of clinical trials, which have shown no evidence of renal toxicity when TDF is used as part of an initial regimen. Our results support the use of TDF as a component of the initial antiretroviral regimen, and suggest that the eGFR should be monitored more closely when TDF is used with a PI/r. (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available